Safety of bevacizumab with fluoropyrimidine-based regimens for first-line teatment of metastatic colorectal cancer

被引：1
|
作者：
Tyagi, Preeta
Chu, Edward
机构：
来源：
CLINICAL COLORECTAL CANCER | 2006年 / 6卷 / 03期
关键词：
D O I：
10.1016/S1533-0028(11)70281-X
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
下载
收藏
页码：189 / 191
页数：3
相关论文
共 50 条
  • [31] Microsatellite instability and sensitivity to fluoropyrimidine and oxaliplatin containing first-line chemotherapy in metastatic colorectal cancer
    Liu, Jia
    Wang, Biao
    Fang, Wentong
    EUROPEAN JOURNAL OF HOSPITAL PHARMACY, 2020, 27 (05) : 267 - 270
  • [32] A comparison of efficacy of first-line chemotherapy regimens for metastatic colorectal cancer (mCRC): FOLFIRI plus bevacizumab vs. XELIRI plus bevacizumab
    Ocvirk, J.
    Rebersek, M.
    Boc, M.
    EJC SUPPLEMENTS, 2009, 7 (02): : 336 - 336
  • [33] Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study
    Van Cutsem, E.
    Rivera, F.
    Berry, S.
    Kretzschmar, A.
    Michael, M.
    DiBartolomeo, M.
    Mazier, M. -A.
    Canon, J. -L.
    Georgoulias, V.
    Peeters, M.
    Bridgewater, J.
    Cunningham, D.
    ANNALS OF ONCOLOGY, 2009, 20 (11) : 1842 - 1847
  • [34] The efficacy and safety of capecitabine plus bevacizumab combination as first-line treatment in elderly metastatic colorectal cancer patients
    Ozcelik, M.
    Odabas, H.
    Ercelep, O.
    Yuksel, S.
    Mert, A. G.
    Aydin, D.
    Surmeli, H.
    Isik, D.
    Isik, S.
    Oyman, A.
    Ustaalioglu, B. B. Oven
    Aliustaoglu, M.
    Gumus, M.
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2016, 18 (06): : 617 - 624
  • [35] The efficacy and safety of capecitabine plus bevacizumab combination as first-line treatment in elderly metastatic colorectal cancer patients
    M. Ozcelik
    H. Odabas
    O. Ercelep
    S. Yuksel
    A. G. Mert
    D. Aydin
    H. Surmeli
    D. Isik
    S. Isik
    A. Oyman
    B. B. Oven Ustaalioglu
    M. Aliustaoglu
    M. Gumus
    Clinical and Translational Oncology, 2016, 18 : 617 - 624
  • [36] Efficacy and safety of first-line chemotherapy plus bevacizumab in patients with metastatic colorectal cancer: a meta-analysis
    Wang Ming
    Zheng Xiaofeng
    Ruan Xiaojiao
    Ye Bailiang
    Cai Long
    Lin Feizhuan
    Tu Jinfu
    Jiang Feizhao
    Li Shaotang
    CHINESE MEDICAL JOURNAL, 2014, 127 (03) : 538 - 546
  • [37] A retrospective observational study on the safety and efficacy of first-line treatment with bevacizumab combined with FOLFIRI in metastatic colorectal cancer
    R López
    M Salgado
    M Reboredo
    C Grande
    J C Méndez
    M Jorge
    C Romero
    G Quintero
    J de la Cámara
    S Candamio
    British Journal of Cancer, 2010, 103 : 1536 - 1541
  • [38] A retrospective observational study on the safety and efficacy of first-line treatment with bevacizumab combined with FOLFIRI in metastatic colorectal cancer
    Lopez, R.
    Salgado, M.
    Reboredo, M.
    Grande, C.
    Mendez, J. C.
    Jorge, M.
    Romero, C.
    Quintero, G.
    de la Camara, J.
    Candamio, S.
    BRITISH JOURNAL OF CANCER, 2010, 103 (10) : 1536 - 1541
  • [39] Safety and efficacy of first-line chemotherapy in unresected metastatic colorectal cancer
    Puthillath, Ajithkumar
    Dunn, Kelli Bullard
    Rajput, Ashwani
    Smith, Judy
    Yang, Gary
    Wilding, Gregory E.
    Tan, Wei
    Gupta, Bhavna
    Fakih, Marwan G.
    CLINICAL COLORECTAL CANCER, 2007, 6 (10) : 710 - 715
  • [40] Bevacizumab in first-line treatment of metastatic breast cancer
    Miles, David
    DRUGS, 2007, 67 (12) : 1800 - 1800
12345